window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : September 28, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Featured

  • Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Almirall and CrystalO partner on small-molecule drug discovery in dermatology

    Almirall has entered a drug discovery collaboration with CrystalO to [...]

    August 17, 2026
  • Advanced Therapies,Drug Discovery & Development,Genomics and sequencing

    Broken String Biosciences launches BaseMap ABE for genome-wide off-target analysis

    Broken String Biosciences has launched BaseMap ABE, a platform designed [...]

    August 10, 2026
  • Digital & Data,Drug Discovery & Development,Manufacturing & Supply Chain,Research & Development

    European consortium demonstrates continuous API manufacturing platform

    A European consortium has validated a continuous manufacturing platform designed [...]

    August 7, 2026
  • Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development

    BioVie reports Phase 2 Parkinson’s trial results for bezisterim

    BioVie has reported topline results from a Phase 2 trial [...]

    August 7, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Research & Development

    LifeMine raises $263 million to advance transplant rejection therapy into Phase 2

    Biotech company LifeMine Therapeutics has raised $263 million to support [...]

    August 7, 2026
  • Digital & Data,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    AI model cuts radiopharmaceutical dose mapping to seconds in prostate cancer study

    A new AI model has generated patient-specific radiation dose-rate maps [...]

    August 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Digital & Data,Drug Discovery & Development,Research & Development

    QuantHealth raises $45M Series B to expand AI clinical trial simulation

    QuantHealth has raised $45 million in a Series B funding [...]

    August 4, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    AB2 Bio receives $30 million as Nippon Shinyaku exercises US option for rare disease drug

    AB2 Bio will receive $30 million from Nippon Shinyaku after [...]

    July 30, 2026
  • Clinical & Regulatory,Digital & Data,Medical devices

    ThinkSono wins FDA clearance for AI-guided ultrasound software for suspected DVT

    ThinkSono has received US FDA 510(k) clearance for ThinkSono Guidance, [...]

    July 31, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development

    Claris Bio raises $118 million to advance potential first drug treatment for LSCD

    Claris Biotherapeutics has raised $118 million in a Series B [...]

    July 29, 2026
Previous345Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Resolution Therapeutics completes Phase 1/2 RTX001 liver disease trial dosing
    Categories: Advanced Therapies, Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Eleva separates biologics platform from Factor H therapy
    Categories: Advanced Therapies, Biotech & Pharma Business, Pharmaceuticals and therapeutics, Research & Development
  • ENA Respiratory begins Phase 2a dosing of nasal antiviral INNA-051
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top